Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab for Resectable Malignant Pleural Mesothelioma
NCT03228537Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in malignant pleural mesothelioma (MPM), sponsored by National Cancer Institute. Primary endpoints: Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy and Safety of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy. Started Jul 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03228537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03228537.